![Jinzi Wu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jinzi Wu
Directeur Général chez ASCLETIS PHARMA INC.
Fortune : 58 M $ au 30/06/2024
Postes actifs de Jinzi Wu
Sociétés | Poste | Début | Fin |
---|---|---|---|
ASCLETIS PHARMA INC. | Directeur Général | - | - |
Président | - | - | |
Fondateur | - | - | |
Ascletis Pharma China Co., Ltd. | Directeur/Membre du Conseil | 01/03/2018 | - |
Gannex LLC | Corporate Officer/Principal | 01/10/2020 | - |
Gannex Pharma Co Ltd. | Directeur Général | 01/01/2019 | - |
Fondateur | 01/01/2019 | - | |
Soundridge Pharmaceuticals (Hong Kong) Co., Ltd. | Directeur/Membre du Conseil | 01/04/2019 | - |
Ascletis Xinnuo Medicine Co., Ltd | Directeur/Membre du Conseil | 01/07/2018 | - |
Directeur Général | 01/07/2018 | - | |
Ascletis BioScience Co., Ltd. | Directeur/Membre du Conseil | 01/04/2013 | - |
Directeur Général | 01/04/2013 | - | |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
![]() Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Directeur Général | - | - |
Président | 07/04/2011 | - | |
Fondateur | 07/04/2011 | - | |
President | 07/04/2011 | - | |
The BayHelix Group | Corporate Officer/Principal | 08/04/2011 | - |
Historique de carrière de Jinzi Wu
Anciens postes connus de Jinzi Wu
Sociétés | Poste | Début | Fin |
---|---|---|---|
░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formation de Jinzi Wu
University of Arizona | Doctorate Degree |
Nanjing University | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 10 |
Chine | 8 |
Suisse | 2 |
Opérationnelle
Corporate Officer/Principal | 10 |
Director/Board Member | 5 |
Chief Executive Officer | 5 |
Sectorielle
Health Technology | 10 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 5 |
---|---|
NOVARTIS AG | Health Technology |
GSK PLC | Health Technology |
SANOFI INDIA LIMITED | Health Technology |
SAGIMET BIOSCIENCES INC. | Health Technology |
ASCLETIS PHARMA INC. | Health Technology |
Entreprise privées | 13 |
---|---|
Immunex Corp.
![]() Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Health Technology |
Novartis Pharmaceuticals Corp.
![]() Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Ambrilia Biopharma, Inc.
![]() Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
![]() Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Health Technology |
The BayHelix Group | |
PhageTech, Inc.
![]() PhageTech, Inc. Miscellaneous Commercial ServicesCommercial Services PhageTech, Inc. provides medical services. The firm develops bacteriophage sensors related tests for detecting analytes in urine, blood, and other body fluids. Its technology is used for advanced diagnostics, such as early stage cancer detection, drug dosage monitoring, and time sensitive diseases and conditions. The company was founded by Richard W. Henson, Gregory Weiss, and Reginald Penner in 2014 and is headquartered in Irvine, CA. | Commercial Services |
Ascletis BioScience Co., Ltd. | |
Gannex Pharma Co Ltd. | |
Ascletis Pharma China Co., Ltd. | |
Ascletis Xinnuo Medicine Co., Ltd | |
Soundridge Pharmaceuticals (Hong Kong) Co., Ltd. | |
Gannex LLC | |
Ascletis Pharmaceuticals Co., Ltd. |